To describe a historical baseline of antimicrobial resistance (AMR) profiles for human clinical Campylobacter species isolates obtained by laboratory surveillance in the province of Saskatchewan from 1999 to 2006; to determine if there were differences in resistance between Campylobacter jejuni and Campylobacter coli; and to determine if there were changes in the annual resistance levels in the two species. One thousand three hundred seventy-eight Campylobacter isolates were subjected to antimicrobial susceptibility testing using the E-test method. Annual resistance levels in C. jejuni and C. coli were compared using logistic regression models. One thousand two hundred (87.1%) isolates were C. jejuni and 129 (9.4%) were C. coli. Resistance in C. jejuni isolates included ciprofloxacin (CIP: 9.4%), erythromycin (ERY: 0.5%), and tetracycline (33.3%). CIP resistance in C. jejuni was higher in 1999 (15.5%, odds ratio [OR] = 3.96, p = 0.01), 2000 (12.7%, OR = 3.10, p = 0.01), 2005 (10.2%, OR = 2.47, p = 0.05), and 2006 (13.0%, OR = 3.22, p = 0.01) compared with 2004 (4.4%). C. coli had significantly higher CIP resistance (15.5%, OR = 1.78, p = 0.03), ERY resistance (13.2%, OR = 60.12, p < 0.01), multidrug resistance (2.3%, OR = 36.29, p < 0.01), and CIP-ERY resistance (3.1%, OR = 50.23, p < 0.01) compared with C. jejuni. This represents the first and most current report of AMR of the collective human Campylobacter isolates from a province in Canada and provides a baseline against which current and future resistance patterns can be compared. Fluoroquinolone resistance in C. jejuni isolates fluctuated from 1999 to 2006, including an increased prevalence in 2005-2006, while macrolide/lincosamide resistance remained very low. Human clinical C. jejuni isolates from Saskatchewan demonstrated resistance to multiple antimicrobials but had significantly less fluoroquinolone and macrolide resistance than C. coli isolates.

中文翻译：

---

加拿大萨斯喀彻温省人类弯曲杆菌属感染的抗菌素耐药性（1999-2006 年）：所有报告病例的历史省级收藏。

描述 1999 年至 2006 年在萨斯喀彻温省通过实验室监测获得的人类临床弯曲杆菌属菌株的抗菌素耐药性 (AMR) 历史基线；确定空肠弯曲杆菌和大肠杆菌之间的耐药性是否存在差异；并确定这两个物种的年抗性水平是否有变化。使用 E-test 方法对 1378 株弯曲杆菌进行了抗微生物药敏试验。使用逻辑回归模型比较了空肠弯曲杆菌和大肠杆菌的年度耐药水平。1,200 株 (87.1%) 分离株为空肠弯曲杆菌，129 株 (9.4%) 为大肠杆菌。空肠弯曲杆菌分离株的耐药性包括环丙沙星（CIP：9.4%）、红霉素（ERY：0.5%）和四环素（33.3%）。1999 年（15.5%，优势比 [OR] = 3.96，p = 0.01）、2000 年（12.7%，OR = 3.10，p = 0.01）、2005 年（10.2%，OR = 2.47， p = 0.05），2006 年（13.0%，OR = 3.22，p = 0.01）与 2004 年（4.4%）相比。大肠杆菌具有显着更高的 CIP 抗性 (15.5%, OR = 1.78, p = 0.03)、ERY 抗性 (13.2%, OR = 60.12, p < 0.01)、多药抗性 (2.3%, OR = 36.29, p < 0.01)和 CIP-ERY 抗性 (3.1%, OR = 50.23, p < 0.01) 与 C. jejuni 相比。这是加拿大一个省的集体人类弯曲杆菌分离株 AMR 的第一份也是最新的报告，并提供了一个基线，可以比较当前和未来的耐药性模式。1999 年至 2006 年间，空肠弯曲杆菌中的氟喹诺酮耐药性波动，包括​​ 2005 年至 2006 年流行率增加，而大环内酯/林可酰胺耐药性仍然很低。来自萨斯喀彻温省的人类临床空肠弯曲杆菌表现出对多种抗菌剂的耐药性，但对氟喹诺酮类和大环内酯类的耐药性明显低于大肠杆菌分离株。